Irccs Istituto Europeo Di Oncologia (IEO); Cure Mediche

Milan, Lombardy 20141

0 studies enrolling now · 2 studies all time

What they study most

Carcinoma, Transitional Cell, Prostatic Neoplasms, Castration-Resistant

Studies at this site

• A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen — Completed
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection — Stopped early